A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients (pts) with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)
Published in
International Journal of Radiation Oncology, Biology, Physics, November 2018
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2020.
All research outputs
#28,640,276
of 34,411,289 outputs
Outputs from International Journal of Radiation Oncology, Biology, Physics
#13,078
of 15,467 outputs
Outputs of similar age
#320,692
of 394,904 outputs
Outputs of similar age from International Journal of Radiation Oncology, Biology, Physics
#181
of 287 outputs
Altmetric has tracked 34,411,289 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,467 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,904 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 287 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
